JP2019509014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019509014A5 JP2019509014A5 JP2018526708A JP2018526708A JP2019509014A5 JP 2019509014 A5 JP2019509014 A5 JP 2019509014A5 JP 2018526708 A JP2018526708 A JP 2018526708A JP 2018526708 A JP2018526708 A JP 2018526708A JP 2019509014 A5 JP2019509014 A5 JP 2019509014A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- polypeptide
- binding
- human
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562258701P | 2015-11-23 | 2015-11-23 | |
| US62/258,701 | 2015-11-23 | ||
| US201562263760P | 2015-12-07 | 2015-12-07 | |
| US62/263,760 | 2015-12-07 | ||
| US201562267343P | 2015-12-15 | 2015-12-15 | |
| US62/267,343 | 2015-12-15 | ||
| US201662320738P | 2016-04-11 | 2016-04-11 | |
| US62/320,738 | 2016-04-11 | ||
| US201662404779P | 2016-10-06 | 2016-10-06 | |
| US62/404,779 | 2016-10-06 | ||
| PCT/EP2016/078395 WO2017089334A1 (en) | 2015-11-23 | 2016-11-22 | Cd39 vascular isoform targeting agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019509014A JP2019509014A (ja) | 2019-04-04 |
| JP2019509014A5 true JP2019509014A5 (enExample) | 2019-12-12 |
Family
ID=57391960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526708A Pending JP2019509014A (ja) | 2015-11-23 | 2016-11-22 | Ｃｄ３９血管アイソフォームターゲティング剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190153113A1 (enExample) |
| EP (1) | EP3380519A1 (enExample) |
| JP (1) | JP2019509014A (enExample) |
| AU (1) | AU2016359790A1 (enExample) |
| CA (1) | CA3005986A1 (enExample) |
| WO (1) | WO2017089334A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3153526B1 (en) | 2008-01-31 | 2020-09-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| AU2018235092B2 (en) | 2017-03-16 | 2024-09-19 | Innate Pharma | Compositions and methods for treating cancer |
| US12226479B2 (en) | 2017-05-11 | 2025-02-18 | The General Hospital Corporation | Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof |
| SG11202000820PA (en) * | 2017-07-31 | 2020-02-27 | Tizona Therapeutics | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| AU2018346447B2 (en) * | 2017-10-06 | 2025-06-19 | Innate Pharma | Restoration of T cell activity via the CD39/CD73 axis |
| IL273440B1 (en) * | 2017-11-15 | 2026-08-01 | Innate Pharma | Strengthening the effect of ATP release |
| JP7800852B2 (ja) * | 2018-01-10 | 2026-01-16 | バイオインヴェント インターナショナル アーベー | 抗体の新規組み合わせおよびその使用 |
| CN112074541A (zh) | 2018-05-03 | 2020-12-11 | 上海岸迈生物科技有限公司 | Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白 |
| UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| EP3806902A4 (en) * | 2018-06-14 | 2022-05-04 | Beth Israel Deaconess Medical Center, Inc. | COMPOSITIONS AND METHODS TO PREVENT OR REVERSE T-CELL DEPLETION BY ECTONUCLEOTIDASE INHIBITION AND ANTIBODY-MEDIATED TARGET CYTOSIS |
| TWI870353B (zh) | 2018-06-18 | 2025-01-21 | 法商天賜製藥公司 | 用於治療癌症之組合物及方法 |
| WO2020146795A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
| ES3070946T3 (en) | 2019-03-12 | 2026-06-18 | Arcus Biosciences Inc | Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation |
| CA3135487A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| KR20220002959A (ko) | 2019-04-23 | 2022-01-07 | 이나뜨 파르마 에스.에이. | Cd73 차단 항체 |
| CN114127121B (zh) | 2019-08-12 | 2025-04-11 | 北京恩瑞尼生物科技股份有限公司 | 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物 |
| KR20220050971A (ko) * | 2019-08-27 | 2022-04-25 | 엘피사이언스 (쑤저우) 바이오파마, 엘티디. | 신규 항-cd39 항체 |
| KR20220062500A (ko) | 2019-09-16 | 2022-05-17 | 서피스 온콜로지, 인크. | 항-cd39 항체 조성물 및 방법 |
| CN110407941B (zh) * | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
| US12391756B2 (en) | 2019-11-05 | 2025-08-19 | Jacobio Pharmaceuticals Co., Ltd. | Binding molecule specific for CD39 and use thereof |
| TW202307006A (zh) * | 2021-06-03 | 2023-02-16 | 美商表面腫瘤學公司 | 用抗ｃｄ３９抗體及派姆單抗治療癌症之方法 |
| TW202340243A (zh) * | 2022-03-03 | 2023-10-16 | 美商阿克思生物科學有限公司 | 抗ｃｄ３９抗體及其用途 |
| CA3248580A1 (en) | 2022-04-29 | 2023-11-02 | Purinomia Biotech, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS CAUSED BY EOSINOPHIL ACTIVITY |
| WO2024115935A1 (en) * | 2022-11-29 | 2024-06-06 | Inserm | Methods for the treatment of b-cell lymphoma using cd39 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3153526B1 (en) * | 2008-01-31 | 2020-09-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
| WO2012085132A1 (en) * | 2010-12-22 | 2012-06-28 | Orega Biotech | Antibodies against human cd39 and use thereof |
| ES2929575T3 (es) * | 2011-06-06 | 2022-11-30 | Novo Nordisk As | Anticuerpos terapéuticos |
-
2016
- 2016-11-22 EP EP16800926.4A patent/EP3380519A1/en not_active Withdrawn
- 2016-11-22 US US15/778,202 patent/US20190153113A1/en not_active Abandoned
- 2016-11-22 WO PCT/EP2016/078395 patent/WO2017089334A1/en not_active Ceased
- 2016-11-22 CA CA3005986A patent/CA3005986A1/en active Pending
- 2016-11-22 AU AU2016359790A patent/AU2016359790A1/en not_active Abandoned
- 2016-11-22 JP JP2018526708A patent/JP2019509014A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3038421T3 (en) | Humanized or chimeric cd3 antibodies | |
| US12227569B2 (en) | Humanized antibodies with increased stability | |
| CN109715663B (zh) | 结合生长抑素受体2的异源二聚抗体 | |
| CN101952454B (zh) | 具有减弱的Fc配体亲和性的抗IFNAR1抗体 | |
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| JP2013545455A5 (enExample) | ||
| JP2014520788A5 (enExample) | ||
| US11299551B2 (en) | Composite binding molecules targeting immunosuppressive B cells | |
| CN112334486B (zh) | 用于治疗癌症的组合物和方法 | |
| JP2018506277A5 (enExample) | ||
| TW202509068A (zh) | 結合ox40l之抗體及使用方法 | |
| EP4417626A1 (en) | Novel antibody-cytokine fusion protein, preparation method therefor and use thereof | |
| US20240352156A1 (en) | Antibodies targeting immunosuppressive b cells | |
| JP2023076596A5 (enExample) | ||
| RU2019123112A (ru) | Анти-il-5 антитела | |
| CA3146977A1 (en) | Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof | |
| RU2015129655A (ru) | Антитело человека, специфичное к матапневмовирусу человека, или антиген-связывающий фрагмент указанного антитела | |
| JP2023511652A (ja) | 鎖間システインが選択的にマッチングされた二重特異性抗体及びその使用 | |
| CN118139639A (zh) | 治疗与免疫抑制b细胞相关联的癌症的方法 | |
| CN110709417A (zh) | 具有突变人IgG4的多肽 | |
| AU2017365367A1 (en) | Monoclonal antibody directed to FGFR1 | |
| KR20210116429A (ko) | 이중특이적 항-cd37 항체를 포함하는 제약 조성물 | |
| WO2018095932A1 (en) | Monoclonal antibody directed to fgfr1 | |
| CN121443643A (zh) | 基于沉默抗体的抗met构建体用于治疗肿瘤和转移 | |
| JP2019517813A5 (enExample) |